#  @LillyOncInt Lilly Oncology International Lilly Oncology International posts on X about dr, more than, breast cancer, watch the most. They currently have [-----] followers and [--] posts still getting attention that total [-------] engagements in the last [--] hours. ### Engagements: [-------] [#](/creator/twitter::1524757692950224904/interactions)  - [--] Week [-------] +5,022,486% - [--] Month [-------] +1,466,479% - [--] Months [---------] +495% - [--] Year [---------] +44% ### Mentions: [--] [#](/creator/twitter::1524757692950224904/posts_active)  - [--] Week [--] +100% - [--] Month [--] +200% - [--] Months [--] +300% - [--] Year [--] +7.70% ### Followers: [-----] [#](/creator/twitter::1524757692950224904/followers)  - [--] Week [-----] +0.51% - [--] Months [-----] +13% - [--] Year [-----] +18% ### CreatorRank: [------] [#](/creator/twitter::1524757692950224904/influencer_rank)  ### Social Influence **Social category influence** [finance](/list/finance) #1207 **Social topic influence** [dr](/topic/dr) 9.62%, [more than](/topic/more-than) #91, [breast cancer](/topic/breast-cancer) 5.77%, [watch](/topic/watch) 5.77%, [share](/topic/share) 5.77%, [science](/topic/science) 5.77%, [how can](/topic/how-can) 3.85%, [future](/topic/future) 3.85%, [has been](/topic/has-been) 3.85%, [education](/topic/education) 3.85% **Top accounts mentioned or mentioned by** [@rodrosb](/creator/undefined) [@wileyglobal](/creator/undefined) [@knowyournodes](/creator/undefined) [@lilly](/creator/undefined) [@mosqueraorgeira](/creator/undefined) [@skyadvising](/creator/undefined) [@jonathanswiftii](/creator/undefined) ### Top Social Posts Top posts by engagements in the last [--] hours "In HR+/HER2 early breast cancer assessing risk of recurrence requires more than one approach. Dr Rodrigo Snchez Bayona explains how clinical features genomic tools biomarkers and multidisciplinary care can refine risk assessment and guide management" [X Link](https://x.com/LillyOncInt/status/2017269099299266727) 2026-01-30T16:10Z [----] followers, 523.1K engagements "The Binet staging system is a key tool in CLL using simple physical findings such as enlarged lymph nodes or detectable spleen/liver involvement to classify disease extent. This helps clinicians estimate risk and guide care" [X Link](https://x.com/LillyOncInt/status/2011466580874637417) 2026-01-14T15:52Z [----] followers, 421.8K engagements "Watch Dr. Marcelo Pitombeira de Lacerda describe how clear compassionate communication and shared decision-making can improve care and empower patients with #HematologicalMalignancy aligning with Lillys commitment to patient-centered care" [X Link](https://x.com/LillyOncInt/status/2019421262645211591) 2026-02-05T14:42Z [----] followers, [---] engagements "The Binet staging system is a key tool in #CLL using simple physical findings such as enlarged lymph nodes or detectable spleen/liver involvement to classify disease extent. This helps clinicians estimate risk and guide care" [X Link](https://x.com/LillyOncInt/status/2021132028565958894) 2026-02-10T08:00Z [----] followers, [---] engagements "In HR+/HER2 #EarlyBreastCancer assessing #RiskOfRecurrence requires more than one approach. Dr @Rodrosb explains how clinical features genomic tools biomarkers and multidisciplinary care can refine risk assessment and guide management" [X Link](https://x.com/anyuser/status/2021932301131673962) 2026-02-12T13:00Z [----] followers, [---] engagements "Bruton's tyrosine kinase (BTK) is an essential component of #BCellReceptor (BCR) signaling. Unregulated BCR signaling plays a vital role in the pathogenesis of B-cell malignancies. How might further understanding of the BTK pathway lead to improvements in outcomes for patients" [X Link](https://x.com/LoxoLillyInt/status/1686633038933880832) 2023-08-02T07:00Z [----] followers, 41K engagements "Identifying those patients with #BreastCancer recurrence before symptoms occur can reduce the risk of death by up to 47%. How can we improve identification of recurrence among asymptomatic patients with breast cancer" [X Link](https://x.com/LoxoLillyInt/status/1689305864413286400) 2023-08-09T16:01Z [----] followers, 14.8K engagements "There are many#QualityofLife (QoL) tools currently used by hematologists.Which one do you find most useful tocapture the QoL needs of patients with hematologic malignancies" [X Link](https://x.com/LoxoLillyInt/status/1691706590154358786) 2023-08-16T07:00Z [----] followers, 24.8K engagements "Caring for patients with#HematologicMalignanciesat home is associated with improvements in quality of life lower hospital admissions and cost of care. What potential benefits of home care do you consider most important" [X Link](https://x.com/LillyOncInt/status/1694967929001898074) 2023-08-25T07:00Z [----] followers, 40.7K engagements "Survivorship in patients with #HematologicMalignanciespresents unique challenges to clinicians. In your opinion what could be the role of psychosocial support and survivorship care planning in addressing the needs of patients with Hematologic Malignancies" [X Link](https://x.com/LillyOncInt/status/1697142311296131197) 2023-08-31T07:00Z [----] followers, 52.7K engagements "Curious to expand your knowledge on #BCellMalignancies Discover more educational resources at the @WileyGlobal Knowledge Hub. #BloodCancerAwarenessMonth" [X Link](https://x.com/LoxoLillyInt/status/1702215755788365884) 2023-09-14T07:00Z [----] followers, 29.7K engagements "Patients with #HematologicalMalignanciesmay be interested in exploring diverse aspects while living with their disease. How can we ensure personalized information meets theneedsof individual patients during #BloodCancerAwarenessMonth and beyond" [X Link](https://x.com/LillyOncInt/status/1705114749044675035) 2023-09-22T07:00Z [----] followers, 20.2K engagements "It was great to connect with the oncology community at #ESMO23 Follow us for highlights and to stay updated on #BreastCancer" [X Link](https://x.com/LoxoLillyInt/status/1716817119852261874) 2023-10-24T14:01Z [----] followers, [----] engagements "#MantleCellLymphoma is associated with a poor prognosis. The 5-year relative survival rate (RSR) stands around 50% varying from about 75% in patients under [--] to approximately 36% in individuals aged [--] and above" [X Link](https://x.com/LoxoLillyInt/status/1777954802183397531) 2024-04-10T07:00Z [----] followers, 28.4K engagements "#BreastCancer is the most common cancer in women worldwide. This #BreastCancerAwarenessMonth lets keep raising awareness and exploring ways to advance care for people living with the disease" [X Link](https://x.com/LillyOncInt/status/1841010196245520709) 2024-10-01T07:00Z [----] followers, 131.5K engagements "The substantial impact of #BreastCancer on patient quality of life underscores the importance of early support to achieve better outcomes. #BreastCancerAwarenessMonth" [X Link](https://x.com/LillyOncInt/status/1841734938237784450) 2024-10-03T07:00Z [----] followers, 138.9K engagements "Among cancer survivors fear of cancer recurrence is the top concern and most cited unmet need according to the Lymphoma Coalition [----] report on the Psychological Impact of Lymphoma. What strategies do you use to help patients manage these issues #WLAD2024 @knowyournodes" [X Link](https://x.com/LillyOncInt/status/1841765134722601051) 2024-10-03T09:00Z [----] followers, 51.2K engagements "Our mission remains the same to deliver life-changing medicines for people living with #cancer. In [----] we brought Loxo Oncologys innovation together with the heritage and global impact of Eli Lilly and Company to become loxo@Lilly. Now we are fully united under Lilly" [X Link](https://x.com/LillyOncInt/status/1842127522810450052) 2024-10-04T09:00Z [----] followers, [---] engagements "There are guidelines available to help physicians support patients with #Lymphoma experiencing psychosocial distress including anxiety depression and fear of recurrence. #Hematology" [X Link](https://x.com/LillyOncInt/status/1842474840516694321) 2024-10-05T08:00Z [----] followers, 16K engagements "Did you know that the first description of #MantleCellLymphoma happened in [----] Weisenburger et al. wrote about [--] cases of #MCL a landmark for the research of this subtype of non-Hodgkin #Lymphoma. Get the latest on MCL through our Hema Pulse series" [X Link](https://x.com/LillyOncInt/status/1845751427227873718) 2024-10-14T09:00Z [----] followers, 59.6K engagements "Discover Dr. Debora Gagliatos expert perspectives on approaches and strategies to enhance care for patients with #BreastCancer" [X Link](https://x.com/LillyOncInt/status/1846476268344111600) 2024-10-16T09:00Z [----] followers, 86.8K engagements "Which tools do you use to support patient adherence Follow us to explore how to improve adherence for patients with #BreastCancer For HCPs Scheduled reminders Educational resources Behavioural strategies Communication tools Scheduled reminders Educational resources Behavioural strategies Communication tools" [X Link](https://x.com/LillyOncInt/status/1848257916190498911) 2024-10-21T07:00Z [----] followers, 68.8K engagements "Did you know that #MantleCellLymphoma represents 7-9% of all lymphomas in Europe Stay tuned to the Hema Pulse series for some revealing statistics and facts about #MCL" [X Link](https://x.com/LillyOncInt/status/1848620341188304981) 2024-10-22T07:00Z [----] followers, 39.8K engagements "What do you believe is the most important supportive care for patients with #BreastCancer For HCPs Psychosocial support Nutritional guidance Other (please comment) Physical exercise program Psychosocial support Nutritional guidance Other (please comment) Physical exercise program" [X Link](https://x.com/LillyOncInt/status/1850809731452977608) 2024-10-28T08:00Z [----] followers, 77K engagements "Dr. Rodrigo Snchez-Bayona highlights the tools used to predict the #RiskOfRecurrence emphasizing the importance of MRD detection. Watch to understand how this could improve risk assessment" [X Link](https://x.com/LillyOncInt/status/1859144781126918465) 2024-11-20T08:00Z [----] followers, 79.8K engagements "Risk assessment in #BreastCancer is essential for clinical decisions. The future of predicting #RiskofRecurrence relies on a personalized approach using diverse tools to accurately gauge recurrence risk and provide tailored patient care" [X Link](https://x.com/LillyOncInt/status/1862043757689864218) 2024-11-28T08:00Z [----] followers, 32.3K engagements "In the management of metastatic #BreastCancer patients have different decision-making styles. Some prefer their doctor to make all the decisions while others prefer a collaborative approach. What strategies do you use to empower your patients to be more involved" [X Link](https://x.com/LillyOncInt/status/1906964799788920846) 2025-04-01T07:00Z [----] followers, 62.2K engagements "Is AI reshaping hematology and improving care in #HematologicalMalignancy Dont miss Dr. Adrian Mosqueras insights as he dives into the topic. 👉 Watch now" [X Link](https://x.com/LillyOncInt/status/1924721875139076595) 2025-05-20T07:00Z [----] followers, 67.8K engagements "1/3 Not all Early Breast Cancer patients are at low riskeven those with [--] positive lymph nodes are at Risk Of Recurrence. What does the data tell us A Thread 🧵" [X Link](https://x.com/LillyOncInt/status/1960960576546337124) 2025-08-28T07:00Z [----] followers, 11.4K engagements "2/3 Some patients with [--] positive nodes have a 30% risk of recurrence over [--] years. This finding reshapes our understanding of therisk profile for those with Early Breast Cancer. A Thread 🧵" [X Link](https://x.com/LillyOncInt/status/1960960623103123483) 2025-08-28T07:00Z [----] followers, [--] engagements "At ESMO [----] we recognize the progress made through years of research innovation and resilience in breast cancer care. From your clinical experience what has been the most important advancement in breast cancer care Early detection tools Targeted therapies AI in cancer care Risk stratification Early detection tools Targeted therapies AI in cancer care Risk stratification" [X Link](https://x.com/LillyOncInt/status/1977630384851448234) 2025-10-13T07:00Z [----] followers, 88.6K engagements "Watch as Dr. Marcelo Pitombeira de Lacerda explores how genetic risk management history and patient preferences guide sequencing strategies. With few direct comparisons clinical judgment remains critical in #CLL care" [X Link](https://x.com/anyuser/status/1996127262270165446) 2025-12-03T08:00Z [----] followers, [---] engagements "Lilly is live at #ASH25 where every conversation helps bring us closer to better care. Explore how we're leading change in #CLL care and join our booth for expert discussions and new perspectives in #Hematology" [X Link](https://x.com/LillyOncInt/status/1997214429151211749) 2025-12-06T08:00Z [----] followers, [---] engagements "CLL is a serious and complex disease. Join our mission to support patient-centered care by following the Lilly Oncology community for expert insights congress news and latest in Hematological Malignancies. Follow us and be part of an advancing patient-focused care" [X Link](https://x.com/LillyOncInt/status/1956281772812947944) 2025-08-15T09:08Z [----] followers, 198.8K engagements "Lilly is proud to continue contributing to the legacy of innovation at ESMO [----]. As the science of breast cancer care evolves we are committed to advancing research that makes a real difference for patients. Join us to explore whats next" [X Link](https://x.com/LillyOncInt/status/1978459948893028561) 2025-10-15T13:56Z [----] followers, 337.1K engagements "As we close ESMO [----] let's reflect on the breakthrough research in breast cancer care. What has been your most impactful takeaway from this year's congress Clinical trial findings Scientific insights Real-world evidence Latest innovations Clinical trial findings Scientific insights Real-world evidence Latest innovations" [X Link](https://x.com/LillyOncInt/status/1979819811212329369) 2025-10-19T08:00Z [----] followers, 111.5K engagements "Breast cancer awareness month may be ending but personalized care is year-round. Whats your go-to strategy to identify high-risk patients Risk assessment tools Genomic testing Team-based decisions Clinical features Risk assessment tools Genomic testing Team-based decisions Clinical features" [X Link](https://x.com/LillyOncInt/status/1981254263578808686) 2025-10-23T07:00Z [----] followers, 75.8K engagements "Interested in education before #ASH25 begins 🗓 Lilly is proud to support an independent symposium where #Hematology experts share the latest on #CLL and SLL: unmet needs emerging approaches managing adverse events and key takeaways for advancing care. 👉Register now https://e.lilly/47ppHCW https://e.lilly/47ppHCW" [X Link](https://x.com/anyuser/status/1996489653155737891) 2025-12-04T08:00Z [----] followers, [---] engagements "Behind every breakthrough at #ASH25 is a patient a story and a purpose. Were honored to join a global community committed to advancing #Hematology through science and innovation. Follow us for updates that matter" [X Link](https://x.com/anyuser/status/1996852039653957892) 2025-12-05T08:00Z [----] followers, [---] engagements "Behind every #CLL diagnosis is a personal journey. Join us at #ASH25 to explore how science and compassion intersect in delivering full-spectrum care" [X Link](https://x.com/anyuser/status/1997576816735764809) 2025-12-07T08:00Z [----] followers, [---] engagements "Which ASH [----] finding was most practice-changing for you Share your reasoning in the comments below. Biomarkers Treatment sequencing PROs/QoL results Novel MOA / targets Biomarkers Treatment sequencing PROs/QoL results Novel MOA / targets" [X Link](https://x.com/anyuser/status/1998301590432764380) 2025-12-09T08:00Z [----] followers, 13.2K engagements "Thank you to the #Hematology community for an inspiring week at #ASH25. Were grateful for the meaningful conversations and shared dedication to advancing hematology care. We look forward to continuing the conversation" [X Link](https://x.com/anyuser/status/1998663979464339893) 2025-12-10T08:00Z [----] followers, [---] engagements "Reflecting on an incredible #ASH25 in Orlando The Lilly team described in one word what being part of this global #Hematology congress meant to them. Proud to stand united in advancing science and shaping the future of patient care" [X Link](https://x.com/anyuser/status/1999132064369578092) 2025-12-11T15:00Z [----] followers, [---] engagements "Effective management of HR-positive HER2-negative Breast Cancer in younger women requires special consideration to help improve outcomes as this group is more likely to experience late recurrence. What factors lead to delayed detection in younger women at risk" [X Link](https://x.com/LillyOncInt/status/1999388754407002549) 2025-12-12T08:00Z [----] followers, [---] engagements "Generative AI is reshaping how we approach medical documentation education and research. Dr. @MosqueraOrgeira explains its emerging applicationsalongside the critical need for clinical oversight and ethical integration" [X Link](https://x.com/anyuser/status/2000475920927195632) 2025-12-15T08:00Z [----] followers, [---] engagements "Beyond diagnosis #CLL patients face daily fatigue impacting quality of life. Regular fatigue assessment & multidisciplinary care can make a meaningful difference. What approaches help empower your patients to live better despite these challenges" [X Link](https://x.com/anyuser/status/2000838305479307602) 2025-12-16T08:00Z [----] followers, [---] engagements "In [----] voices from across the global community came together to exchange ideas share knowledge and help move care forward in #CLL #MCL and #BreastCancer. Thank you to everyone who engaged contributed and helped shape the conversation. We look ahead to 2026" [X Link](https://x.com/anyuser/status/2003375021041852911) 2025-12-23T08:00Z [----] followers, [---] engagements "Even patients with a low nodal burden may face a high #RiskOfRecurrence in HR+/HER2- #EarlyBreastCancer. Watch Professor Marc Thill provide his expert perspective on why even a low nodal burden influences long-term recurrence risk and survival" [X Link](https://x.com/anyuser/status/2010985167460983096) 2026-01-13T08:00Z [----] followers, [----] engagements "Patients with #HematologicalMalignancy have different information preferences. In a multicenter study of [---] patients most preferred multiple ways to hear about treatment success and 88% favored percentages. Aligning communication with preferences supports better decisions" [X Link](https://x.com/LillyOncInt/status/2011785438239871401) 2026-01-15T13:00Z [----] followers, [---] engagements "Cancer guidelines recommend that clinicians should provide diagnostic and prognostic information that is tailored to patient needs and provides reassurance without misleading the patient including those with #HematologicalMalignancy" [X Link](https://x.com/anyuser/status/2013521882721530348) 2026-01-20T08:00Z [----] followers, [---] engagements "Management of HR+ HER2 #EarlyBreastCancer continues to evolve but long-term recurrence remains a challenge for many patients even after [--] years. Recognizing those at risk can improve outcomes. Follow for more" [X Link](https://x.com/anyuser/status/2016058595314483239) 2026-01-27T08:00Z [----] followers, [---] engagements "More than 40% of patients with #Lymphoma do not feel well informed about their healthcare according to a Lymphoma Coalition report. Read the full report here: https://e.lilly/4bPVWxS https://e.lilly/4bPVWxS" [X Link](https://x.com/anyuser/status/2016858869088039126) 2026-01-29T13:00Z [----] followers, [---] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@LillyOncInt Lilly Oncology International
Lilly Oncology International posts on X about dr, more than, breast cancer, watch the most. They currently have [-----] followers and [--] posts still getting attention that total [-------] engagements in the last [--] hours.
Engagements: [-------] #
- [--] Week [-------] +5,022,486%
- [--] Month [-------] +1,466,479%
- [--] Months [---------] +495%
- [--] Year [---------] +44%
Mentions: [--] #
- [--] Week [--] +100%
- [--] Month [--] +200%
- [--] Months [--] +300%
- [--] Year [--] +7.70%
Followers: [-----] #
- [--] Week [-----] +0.51%
- [--] Months [-----] +13%
- [--] Year [-----] +18%
CreatorRank: [------] #
Social Influence
Social category influence finance #1207
Social topic influence dr 9.62%, more than #91, breast cancer 5.77%, watch 5.77%, share 5.77%, science 5.77%, how can 3.85%, future 3.85%, has been 3.85%, education 3.85%
Top accounts mentioned or mentioned by @rodrosb @wileyglobal @knowyournodes @lilly @mosqueraorgeira @skyadvising @jonathanswiftii
Top Social Posts
Top posts by engagements in the last [--] hours
"In HR+/HER2 early breast cancer assessing risk of recurrence requires more than one approach. Dr Rodrigo Snchez Bayona explains how clinical features genomic tools biomarkers and multidisciplinary care can refine risk assessment and guide management"
X Link 2026-01-30T16:10Z [----] followers, 523.1K engagements
"The Binet staging system is a key tool in CLL using simple physical findings such as enlarged lymph nodes or detectable spleen/liver involvement to classify disease extent. This helps clinicians estimate risk and guide care"
X Link 2026-01-14T15:52Z [----] followers, 421.8K engagements
"Watch Dr. Marcelo Pitombeira de Lacerda describe how clear compassionate communication and shared decision-making can improve care and empower patients with #HematologicalMalignancy aligning with Lillys commitment to patient-centered care"
X Link 2026-02-05T14:42Z [----] followers, [---] engagements
"The Binet staging system is a key tool in #CLL using simple physical findings such as enlarged lymph nodes or detectable spleen/liver involvement to classify disease extent. This helps clinicians estimate risk and guide care"
X Link 2026-02-10T08:00Z [----] followers, [---] engagements
"In HR+/HER2 #EarlyBreastCancer assessing #RiskOfRecurrence requires more than one approach. Dr @Rodrosb explains how clinical features genomic tools biomarkers and multidisciplinary care can refine risk assessment and guide management"
X Link 2026-02-12T13:00Z [----] followers, [---] engagements
"Bruton's tyrosine kinase (BTK) is an essential component of #BCellReceptor (BCR) signaling. Unregulated BCR signaling plays a vital role in the pathogenesis of B-cell malignancies. How might further understanding of the BTK pathway lead to improvements in outcomes for patients"
X Link 2023-08-02T07:00Z [----] followers, 41K engagements
"Identifying those patients with #BreastCancer recurrence before symptoms occur can reduce the risk of death by up to 47%. How can we improve identification of recurrence among asymptomatic patients with breast cancer"
X Link 2023-08-09T16:01Z [----] followers, 14.8K engagements
"There are many#QualityofLife (QoL) tools currently used by hematologists.Which one do you find most useful tocapture the QoL needs of patients with hematologic malignancies"
X Link 2023-08-16T07:00Z [----] followers, 24.8K engagements
"Caring for patients with#HematologicMalignanciesat home is associated with improvements in quality of life lower hospital admissions and cost of care. What potential benefits of home care do you consider most important"
X Link 2023-08-25T07:00Z [----] followers, 40.7K engagements
"Survivorship in patients with #HematologicMalignanciespresents unique challenges to clinicians. In your opinion what could be the role of psychosocial support and survivorship care planning in addressing the needs of patients with Hematologic Malignancies"
X Link 2023-08-31T07:00Z [----] followers, 52.7K engagements
"Curious to expand your knowledge on #BCellMalignancies Discover more educational resources at the @WileyGlobal Knowledge Hub. #BloodCancerAwarenessMonth"
X Link 2023-09-14T07:00Z [----] followers, 29.7K engagements
"Patients with #HematologicalMalignanciesmay be interested in exploring diverse aspects while living with their disease. How can we ensure personalized information meets theneedsof individual patients during #BloodCancerAwarenessMonth and beyond"
X Link 2023-09-22T07:00Z [----] followers, 20.2K engagements
"It was great to connect with the oncology community at #ESMO23 Follow us for highlights and to stay updated on #BreastCancer"
X Link 2023-10-24T14:01Z [----] followers, [----] engagements
"#MantleCellLymphoma is associated with a poor prognosis. The 5-year relative survival rate (RSR) stands around 50% varying from about 75% in patients under [--] to approximately 36% in individuals aged [--] and above"
X Link 2024-04-10T07:00Z [----] followers, 28.4K engagements
"#BreastCancer is the most common cancer in women worldwide. This #BreastCancerAwarenessMonth lets keep raising awareness and exploring ways to advance care for people living with the disease"
X Link 2024-10-01T07:00Z [----] followers, 131.5K engagements
"The substantial impact of #BreastCancer on patient quality of life underscores the importance of early support to achieve better outcomes. #BreastCancerAwarenessMonth"
X Link 2024-10-03T07:00Z [----] followers, 138.9K engagements
"Among cancer survivors fear of cancer recurrence is the top concern and most cited unmet need according to the Lymphoma Coalition [----] report on the Psychological Impact of Lymphoma. What strategies do you use to help patients manage these issues #WLAD2024 @knowyournodes"
X Link 2024-10-03T09:00Z [----] followers, 51.2K engagements
"Our mission remains the same to deliver life-changing medicines for people living with #cancer. In [----] we brought Loxo Oncologys innovation together with the heritage and global impact of Eli Lilly and Company to become loxo@Lilly. Now we are fully united under Lilly"
X Link 2024-10-04T09:00Z [----] followers, [---] engagements
"There are guidelines available to help physicians support patients with #Lymphoma experiencing psychosocial distress including anxiety depression and fear of recurrence. #Hematology"
X Link 2024-10-05T08:00Z [----] followers, 16K engagements
"Did you know that the first description of #MantleCellLymphoma happened in [----] Weisenburger et al. wrote about [--] cases of #MCL a landmark for the research of this subtype of non-Hodgkin #Lymphoma. Get the latest on MCL through our Hema Pulse series"
X Link 2024-10-14T09:00Z [----] followers, 59.6K engagements
"Discover Dr. Debora Gagliatos expert perspectives on approaches and strategies to enhance care for patients with #BreastCancer"
X Link 2024-10-16T09:00Z [----] followers, 86.8K engagements
"Which tools do you use to support patient adherence Follow us to explore how to improve adherence for patients with #BreastCancer For HCPs Scheduled reminders Educational resources Behavioural strategies Communication tools Scheduled reminders Educational resources Behavioural strategies Communication tools"
X Link 2024-10-21T07:00Z [----] followers, 68.8K engagements
"Did you know that #MantleCellLymphoma represents 7-9% of all lymphomas in Europe Stay tuned to the Hema Pulse series for some revealing statistics and facts about #MCL"
X Link 2024-10-22T07:00Z [----] followers, 39.8K engagements
"What do you believe is the most important supportive care for patients with #BreastCancer For HCPs Psychosocial support Nutritional guidance Other (please comment) Physical exercise program Psychosocial support Nutritional guidance Other (please comment) Physical exercise program"
X Link 2024-10-28T08:00Z [----] followers, 77K engagements
"Dr. Rodrigo Snchez-Bayona highlights the tools used to predict the #RiskOfRecurrence emphasizing the importance of MRD detection. Watch to understand how this could improve risk assessment"
X Link 2024-11-20T08:00Z [----] followers, 79.8K engagements
"Risk assessment in #BreastCancer is essential for clinical decisions. The future of predicting #RiskofRecurrence relies on a personalized approach using diverse tools to accurately gauge recurrence risk and provide tailored patient care"
X Link 2024-11-28T08:00Z [----] followers, 32.3K engagements
"In the management of metastatic #BreastCancer patients have different decision-making styles. Some prefer their doctor to make all the decisions while others prefer a collaborative approach. What strategies do you use to empower your patients to be more involved"
X Link 2025-04-01T07:00Z [----] followers, 62.2K engagements
"Is AI reshaping hematology and improving care in #HematologicalMalignancy Dont miss Dr. Adrian Mosqueras insights as he dives into the topic. 👉 Watch now"
X Link 2025-05-20T07:00Z [----] followers, 67.8K engagements
"1/3 Not all Early Breast Cancer patients are at low riskeven those with [--] positive lymph nodes are at Risk Of Recurrence. What does the data tell us A Thread 🧵"
X Link 2025-08-28T07:00Z [----] followers, 11.4K engagements
"2/3 Some patients with [--] positive nodes have a 30% risk of recurrence over [--] years. This finding reshapes our understanding of therisk profile for those with Early Breast Cancer. A Thread 🧵"
X Link 2025-08-28T07:00Z [----] followers, [--] engagements
"At ESMO [----] we recognize the progress made through years of research innovation and resilience in breast cancer care. From your clinical experience what has been the most important advancement in breast cancer care Early detection tools Targeted therapies AI in cancer care Risk stratification Early detection tools Targeted therapies AI in cancer care Risk stratification"
X Link 2025-10-13T07:00Z [----] followers, 88.6K engagements
"Watch as Dr. Marcelo Pitombeira de Lacerda explores how genetic risk management history and patient preferences guide sequencing strategies. With few direct comparisons clinical judgment remains critical in #CLL care"
X Link 2025-12-03T08:00Z [----] followers, [---] engagements
"Lilly is live at #ASH25 where every conversation helps bring us closer to better care. Explore how we're leading change in #CLL care and join our booth for expert discussions and new perspectives in #Hematology"
X Link 2025-12-06T08:00Z [----] followers, [---] engagements
"CLL is a serious and complex disease. Join our mission to support patient-centered care by following the Lilly Oncology community for expert insights congress news and latest in Hematological Malignancies. Follow us and be part of an advancing patient-focused care"
X Link 2025-08-15T09:08Z [----] followers, 198.8K engagements
"Lilly is proud to continue contributing to the legacy of innovation at ESMO [----]. As the science of breast cancer care evolves we are committed to advancing research that makes a real difference for patients. Join us to explore whats next"
X Link 2025-10-15T13:56Z [----] followers, 337.1K engagements
"As we close ESMO [----] let's reflect on the breakthrough research in breast cancer care. What has been your most impactful takeaway from this year's congress Clinical trial findings Scientific insights Real-world evidence Latest innovations Clinical trial findings Scientific insights Real-world evidence Latest innovations"
X Link 2025-10-19T08:00Z [----] followers, 111.5K engagements
"Breast cancer awareness month may be ending but personalized care is year-round. Whats your go-to strategy to identify high-risk patients Risk assessment tools Genomic testing Team-based decisions Clinical features Risk assessment tools Genomic testing Team-based decisions Clinical features"
X Link 2025-10-23T07:00Z [----] followers, 75.8K engagements
"Interested in education before #ASH25 begins 🗓 Lilly is proud to support an independent symposium where #Hematology experts share the latest on #CLL and SLL: unmet needs emerging approaches managing adverse events and key takeaways for advancing care. 👉Register now https://e.lilly/47ppHCW https://e.lilly/47ppHCW"
X Link 2025-12-04T08:00Z [----] followers, [---] engagements
"Behind every breakthrough at #ASH25 is a patient a story and a purpose. Were honored to join a global community committed to advancing #Hematology through science and innovation. Follow us for updates that matter"
X Link 2025-12-05T08:00Z [----] followers, [---] engagements
"Behind every #CLL diagnosis is a personal journey. Join us at #ASH25 to explore how science and compassion intersect in delivering full-spectrum care"
X Link 2025-12-07T08:00Z [----] followers, [---] engagements
"Which ASH [----] finding was most practice-changing for you Share your reasoning in the comments below. Biomarkers Treatment sequencing PROs/QoL results Novel MOA / targets Biomarkers Treatment sequencing PROs/QoL results Novel MOA / targets"
X Link 2025-12-09T08:00Z [----] followers, 13.2K engagements
"Thank you to the #Hematology community for an inspiring week at #ASH25. Were grateful for the meaningful conversations and shared dedication to advancing hematology care. We look forward to continuing the conversation"
X Link 2025-12-10T08:00Z [----] followers, [---] engagements
"Reflecting on an incredible #ASH25 in Orlando The Lilly team described in one word what being part of this global #Hematology congress meant to them. Proud to stand united in advancing science and shaping the future of patient care"
X Link 2025-12-11T15:00Z [----] followers, [---] engagements
"Effective management of HR-positive HER2-negative Breast Cancer in younger women requires special consideration to help improve outcomes as this group is more likely to experience late recurrence. What factors lead to delayed detection in younger women at risk"
X Link 2025-12-12T08:00Z [----] followers, [---] engagements
"Generative AI is reshaping how we approach medical documentation education and research. Dr. @MosqueraOrgeira explains its emerging applicationsalongside the critical need for clinical oversight and ethical integration"
X Link 2025-12-15T08:00Z [----] followers, [---] engagements
"Beyond diagnosis #CLL patients face daily fatigue impacting quality of life. Regular fatigue assessment & multidisciplinary care can make a meaningful difference. What approaches help empower your patients to live better despite these challenges"
X Link 2025-12-16T08:00Z [----] followers, [---] engagements
"In [----] voices from across the global community came together to exchange ideas share knowledge and help move care forward in #CLL #MCL and #BreastCancer. Thank you to everyone who engaged contributed and helped shape the conversation. We look ahead to 2026"
X Link 2025-12-23T08:00Z [----] followers, [---] engagements
"Even patients with a low nodal burden may face a high #RiskOfRecurrence in HR+/HER2- #EarlyBreastCancer. Watch Professor Marc Thill provide his expert perspective on why even a low nodal burden influences long-term recurrence risk and survival"
X Link 2026-01-13T08:00Z [----] followers, [----] engagements
"Patients with #HematologicalMalignancy have different information preferences. In a multicenter study of [---] patients most preferred multiple ways to hear about treatment success and 88% favored percentages. Aligning communication with preferences supports better decisions"
X Link 2026-01-15T13:00Z [----] followers, [---] engagements
"Cancer guidelines recommend that clinicians should provide diagnostic and prognostic information that is tailored to patient needs and provides reassurance without misleading the patient including those with #HematologicalMalignancy"
X Link 2026-01-20T08:00Z [----] followers, [---] engagements
"Management of HR+ HER2 #EarlyBreastCancer continues to evolve but long-term recurrence remains a challenge for many patients even after [--] years. Recognizing those at risk can improve outcomes. Follow for more"
X Link 2026-01-27T08:00Z [----] followers, [---] engagements
"More than 40% of patients with #Lymphoma do not feel well informed about their healthcare according to a Lymphoma Coalition report. Read the full report here: https://e.lilly/4bPVWxS https://e.lilly/4bPVWxS"
X Link 2026-01-29T13:00Z [----] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing